ArticleCancer causes & control : CCC2026
Age and sex differences in the global cancer burden.
Article in Cancer causes & control : CCC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study is to describe the 2022 cancer burden by sex and age group globally, as well as by world region.
methodsWe utilized GLOBOCAN 2022 estimates to quantify overall and cancer-specific incidence and mortality using counts and age-standardized rates (ASRs; per 100,000) simultaneously stratified by sex and age bands (0-14, 15-29, 30-39, 40-49, 50-59, 60-69, 70-79, and 80 + years), globally and by world region.
resultsIn 2022, an estimated 18.7 million cases (excluding nonmelanoma skin cancer) and 9.7 million cancer-related deaths occurred globally, of which 51 and 56%, respectively, occurred in males. Cases increased with age, peaking at 60-69, while cancer-related deaths peaked at 70-79. Females had higher burdens in age bands spanning 30-59, driven by female-specific cancers, whereas males dominated in older age groups primarily due to lung and prostate cancers. Regional patterns varied considerably. In parts of Africa and Asia, nearly half of female cases occurred before age 50, contrasting with Europe, North America, and Australia/New Zealand, where cases were concentrated at older ages. Mortality patterns often mirrored incidence but were disproportionately high in transitioning regions and younger age bands, indicating a greater adverse impact of limited access to early detection and treatment. Finally, regional cancer hotspots were identified and discussed.
conclusionThese findings serve as a reference for the global cancer community to guide future research and inform cancer control initiatives, highlighting the need for age- and sex-specific, and regionally tailored strategies.
Indexed as
Identifiers
42570134What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.